Navigation Links
Synthetic Biologics to Report Second Quarter 2013 Financial Results
Date:8/8/2013

ROCKVILLE, Md., Aug. 8, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that it intends to release its financial results for the second quarter ended June 30, 2013 on Wednesday, August 14, 2013.

The Company will hold an investor conference call on Wednesday, August 14, 2013, at 4:00 pm EDT. During the call, Jeffrey Riley, Synthetic Biologics' Chief Executive Officer, will provide a brief update of the Company's multiple sclerosis program and its infectious disease pipeline, including its oral enzyme candidate for the prevention of C. difficile infections and monoclonal antibody candidates for the treatment of Pertussis and Acinetobacter infections. C. Evan Ballantyne, Synthetic Biologics' Chief Financial Officer, will review the Company's financial results for the second quarter ended June 30, 2013.

Interested parties should call 1-800-860-2442 (U.S. toll free), 1-866-605-3852 (Canada), or +1 412-858-4600 (International), fifteen minutes before the start of the call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question & Answer Session. The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=95523. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, http://www.videonewswire.com/event.asp?id=95523 for 30 days after the call.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
2. Synthetic Biology: Emerging Global Markets
3. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
4. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
5. Startling results in synthetic chemistry presented in Nature Chemistry
6. Adeona Becomes Synthetic Biologics, Inc.
7. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
8. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
9. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
10. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
11. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , September 17, 2014 ... mode of action from a truly novel ... MGB Biopharma, a biopharmaceutical company ... announces today that it has secured £4.0m ... lead antibacterial, MGB-BP-3, against a range of ...
(Date:9/16/2014)... , Sept. 16, 2014 This report analyzes ... following Product Segments: Software, Hardware, and Biocontent. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ... seven-year historic analysis is provided for these markets. Market data ...
(Date:9/16/2014)... University scientists who created a deicing film for radar ... a transparent coating for glass. , The new ... could keep glass surfaces from windshields to skyscrapers free ... radio frequencies (RF). , The technology was introduced ... Applied Materials and Interfaces . , The material ...
(Date:9/16/2014)... , Sept. 16, 2014  The Council for ... support organization in the country, today released a ... . It showed that in ... Carolina startups in the technology, life ... global investment from a variety of sources. Significant investment ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23Nanoribbon film keeps glass ice-free 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4
... and improved seizure freedom versus placebo when ... (AEDs)- Phase III study supports recent U.S. ... Jan. 27 The new antiepileptic drug ... adult partial-onset epilepsy patients whose seizures were ...
... Canada, Jan. 27 InNexus Biotechnology Inc. (OTC Bulletin ... today that it has completed a second private placement ... placement that was completed 12 December 2008.The private placement, ... Debenture will be convertible into common shares of InNexus ...
... (CTI),(Nasdaq and MTA: CTIC) announced today that the ... Letter") from the Listing,Qualifications Staff (the "Staff") of ... not comply with Marketplace Rule 4350(i)(1)(C) when the,Company ... ("SMI"),and issued additional common shares to SMI shareholders. ...
Cached Biology Technology:Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 2Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 3Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 4Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 5InNexus Completes Previously Announced Private Placement 2Cell Therapeutics Receives Additional NASDAQ Notification 2Cell Therapeutics Receives Additional NASDAQ Notification 3Cell Therapeutics Receives Additional NASDAQ Notification 4
(Date:9/16/2014)... 13, 2014. The fire is human-caused and is ... in size and is mostly being fueled by grass ... night due to higher humidity. Yesterday (8/15), firefighters ... construct a fireline on the West and North sides of ... fire: , 7 20-person Crews, 4 Hot Shot Crews, 1 ...
(Date:9/16/2014)... take up residence in and on the human body ... according to new research at Washington University School of ... individuals carry about five types of viruses on their ... Biology . The study is the first comprehensive analysis ... , The research was conducted as part of ...
(Date:9/16/2014)... for the dinosaurs 66 million years ago decimated the ... extent than their deciduous peers, according to a study ... the journal PLOS Biology . , Applying ... fossilized leaves of angiosperms flowering plants excluding ... ecology of a diverse plant community thriving during a ...
Breaking Biology News(10 mins):Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4
... St. Louis, MO, June 1, 2010 Making food choices ... according to a new study comparing the nutritional content of ... the June issue of the Journal of the American ... diet consisting entirely of advertised foods would contain 25 times ...
... Arbor, Mich. University of Michigan scientists have provided the ... brain that influences the effectiveness of serotonin-related antidepressants, such as ... ahead of print in the journal Proceedings of the ... a more targeted treatment of depression and anxiety with fewer ...
... have identified three new susceptibility genes in a genome-wide ... by the Genome Institute of Singapore (GIS), a biomedical ... Research (A*STAR), and the Sun Yat-Sen University Cancer Centre, ... understanding of the important role played by host genetic ...
Cached Biology News:TV food advertisements promote imbalanced diets 2Animal study reveals new target for antidepressants 2Scientists find genes associated with throat cancer through study of over 10,000 subjects 2Scientists find genes associated with throat cancer through study of over 10,000 subjects 3
...
... organic acid analysis standard is ... organic salts; molecular weights range ... standard is provided for use ... and the organic acid analysis ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
Biology Products: